Mortality among patients undergoing dipyridamole 99mTc Sestamibi SPECT: impact of blunted heart rate response and abnormal scans

Autor:	D Vorobeichik Pechersky, E Goshen, A Migranov, D Geva, Ronen Rubinshtein, A Izhaki
Rok vydání:	2021
Předmět:	Dipyridamole medicine.medical_specialty business.industry Internal medicine Cardiology Medicine Cardiology and Cardiovascular Medicine business 99mTc Sestamibi medicine.drug Heart rate response
Zdroj:	European Heart Journal. 42
ISSN:	1522-9645 0195-668X
DOI:	10.1093/eurheartj/ehab724.0252
Popis:	Background Blunted heart rate response (BHRR) caused by cardiac neuropathy associated with dipyridamole stress, has been linked to cardiovascular (CV) outcome events. Whether BHRR is necessarily associated with abnormal perfusion is unknown. The aim of the study was to assess the incremental prognostic value of BHRR in a single center population undergoing Dipyridamole 99mTc Sestamibi SPECT test (DSPECT) for predicting late CV events. Methods 388 patients (aged 73±10 years, 45% females, 51% with known coronary disease) that underwent DSPECT over 3 years period were included. Abnormal DSPECT and BHRR were evaluated in relation to late death. Results Mean follow up period was 1560±565 (15–2431) days. During follow up period, 90 patients died. Mode of death was CV in 20 and non-CV in 70. BHRR ( Conclusions In this contemporary DSPECT cohort, BHRR and DSPECT failed to predict all-cause mortality. However, BHRR was an independent predictor of CV death. Funding Acknowledgement Type of funding sources: None. BHRR stratifies abnormal DSPECT
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::6ec0fb7168f0890c04f42685779e5b4b https://doi.org/10.1093/eurheartj/ehab724.0252 Zobrazit plný text záznamu